Pharmstandard was among the participants in the series B round, which lifted Jounce's overall funding above the $100m mark.
US-based immunotherapy product developer Jounce Therapeutics closed an oversubscribed series B round at $56m today after raising money from investors including pharmaceutical firm Pharmstandard International.
Wellington Management Company, Redmile Group, Nextech Invest, Cormorant Asset Management, Omega Funds, Casdin Capital, Foresite Capital Management and an unnamed blue chip public investment fund also participated in the round.
Launched by venture capital firm Third Rock Ventures in 2014 with $47m of series A financing, Jounce is developing immunotherapy products to treat cancer.
The…
